Skip to main content
David Wise, MD, Oncology, New York, NY

DavidRWiseMDPhD

Oncology • New York, NY

Genitourinary Oncology, Hematologic Oncology

Director, Genitourinary Medical Oncology, Department of Medicine, NYU Perlmutter Cancer Center

Join to view full profile

Dr. Wise is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wise's full profile

Already have an account?

  • Office

    160 East 34th Street
    10th Floor
    New York, NY 10016
    Phone+1 212-731-6366
    Fax+1 212-731-5527

Summary

  • My expertise in the management of advanced urologic cancers incorporates the most recently developed imaging and therapeutic modalities and a broad array of targeted and immunotherapy-based clinical trials.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2011 - 2013
  • Other
    OtherClass of 2011
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2011

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2013 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • EU Thumbs up for Oral ADT for Prostate Cancer
    EU Thumbs up for Oral ADT for Prostate CancerFebruary 28th, 2022
  • Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations
    Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 MutationsSeptember 24th, 2019
  • European Urologists Release Position Paper on Immune Checkpoint Inhibitor Toxicities
    European Urologists Release Position Paper on Immune Checkpoint Inhibitor ToxicitiesAugust 2nd, 2019
  • Join now to see all

Dr. David Wise, Dr. David Wise, MD, Dr. D Wise, Dr. David R Wise